Salvador GARCIA García Carmona

Dr. Salvador GARCIA García Carmona

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSalvador GARCIA García Carmona
Salvador GARCIA García Carmona
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
IAItzel Abigail Veronica Aguilar
Itzel Abigail Veronica Aguilar
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
Leslie Chavez-GalanLeslie Chavez-Galan
Leslie Chavez-Galan
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Background: Genetic susceptibility to infectious diseases is partly due to the variation in the human genome, and COVID-19 is not the exception. This study aimed to identify whether risk alleles of known genes linked with emphysema (SERPINA1) and pulmonary fibrosis (MUC5B) are associated with severe COVID-19, and whether plasma mucin 5B differs according to patients’ outcomes. Materials and methods: We included 1258 Mexican subjects diagnosed with COVID-19. We genotyped rs2892474 and rs17580 of the SERPINA1 gene and rs35705950 of MUC5B. Based on the rs35705950 genotypes, mucin 5B plasma protein levels were quantified. Results: Homozygous for the risk alleles of the three polymorphisms were found in less than 5% of the study population, but no statistically significant difference in the genotype or allele association analysis. At the protein level, non-survivors carrying one or two copies of the risk allele rs35705950 in MUC5B (GT + TT) had lower levels of mucin 5B compared to the survivors (0.0 vs. 0.17 ng/mL, p = 0.0013). Conclusion: The polymorphisms rs28929474 and rs17580 of SERPINA1 and rs35705950 of MUC5B are not associated with the risk of severe COVID-19 in the Mexican population. COVID-19 survivor patients bearing one or two copies of the rs35705950 risk allele have higher plasma levels of mucin 5B.

Verified
Journal Article
Open access
PDF file
OROreth Montero Ruíz
Oreth Montero Ruíz
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
DRDaniela Guadalupe Valencia-Pérez Rea
Daniela Guadalupe Valencia-Pérez Rea
GRGibran E. Rueda-Munive
Gibran E. Rueda-Munive
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Background: This study was conducted to identify genetic risk variants associated with nicotine addiction in the CHRNA5, HTR2A, DRD4, and CYP2A6 genes among electronic cigarette users who also smoke combustible cigarettes (dual users), and to assess potential genotoxic and cytotoxic damage in the oral mucosal cells of the study population. Methods: We included dual e-cig users (ECIG, n = 70), combustible cigarette smokers (CCU, n = 24), and non-smokers and non-e-cig users (NS, n = 110). Genetic variants in CHRNA5, HTR2A, DRD4, and CYP2A6 were genotyped. Micronucleus analysis was performed on oral mucosal cells to detect cellular abnormalities. Results: The ECIG group demonstrated greater nicotine addiction on the Fagerström Test for Nicotine Dependence (FTND, 5.5 vs. 1, p = 0.023). Salivary cotinine levels were significantly higher in the ECIG group compared to the CCU group (39 vs. 12 ng/mL, p < 0.001). The carriers of the A allele (rs16969968/CHRNA5) had higher FTND scores, carriers of the C allele (rs1800955/DRD4) used electronic cigarettes more frequently each day, and carriers of the T allele (rs4105144/CYP2A6) started using nicotine products at a younger age. The number of micronuclei and cellular abnormalities in the oral mucosa was higher in the ECIG and CCU groups compared to the NS group. Conclusions: Salivary cotinine levels and FTND are higher in dual e-cigarette users than in combustible cigarette users. Dual users exhibit risk alleles in the CHRNA5, DRD4, and CYP2A6 genes, which are associated with traits linked to increased nicotine addiction. Dual e-cigarette use poses comparable genotoxic risks to combustible smoking.

Verified
Journal Article
Open access
PDF file
IFIngrid Fricke-Galindo
Ingrid Fricke-Galindo
SCSalvador GARCIA García Carmona
Salvador GARCIA García Carmona
Brandon Bautista-BecerrilBrandon Bautista-Becerril
Brandon Bautista-Becerril
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
Genetic variants related to susceptibility to chronic respiratory conditions such as interstitial lung disease (ILD) could share critical pathways in the pathogenesis of COVID-19 and be implicated in COVID-19 outcomes and post-COVID-19. We aimed to identify the participation of genetic variants in lung function and ILD genes in severe COVID-19 outcomes and post-COVID-19 condition. We studied 936 hospitalized patients with COVID-19. The requirement of invasive mechanical ventilation (IMV) and the acute respiratory distress syndrome (ARDS) classification were considered. The mortality was assessed as the in-hospital death. The post-COVID-19 group included 102 patients evaluated for pulmonary function tests four times during the year after discharge. Five variants (FAM13A rs2609255, DSP rs2076295, TOLLIP rs111521887, TERT rs2736100, and THSD4 rs872471) were genotyped using TaqMan assays. A multifactor dimensionality reduction method (MDR) was performed for epistasis estimation. The TERT rs2736100 and THSD4 rs872471 variants were associated with differential risk for ARDS severity (moderate vs. severe, CC + CA, p = 0.044, OR = 0.66, 95% CI = 0.44–0.99; and GG p = 0.034, OR = 2.22, 95% CI = 1.04–4.72, respectively). These variants and FAM13A rs2609255 were also related to pulmonary function post-COVID-19. The MDR analysis showed differential epistasis and correlation of the genetic variants included in this study. The well-known variants in recognized genes related to pulmonary function worsening and interstitial disorders are related to the severity and mortality of COVID-19 and lung performance in the post-COVID-19 condition.

23 July 2025 in Epigenomics
Verified
Journal Article
Open access
SCSalvador GARCIA García Carmona
Salvador GARCIA García Carmona
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
Juan Carlos Fernandez-LopezJuan Carlos Fernandez-Lopez
Juan Carlos Fernandez-Lopez
ARAlejandra Ramirez
Alejandra Ramirez
FMFernando Morales-González
Fernando Morales-González
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Exposure to smoke from biomass combustion is a significant environmental risk factor for chronic obstructive pulmonary disease (COPD). Through epigenome-wide association studies (EWAS), changes in DNA methylation levels associated with pathological conditions can be identified. We aimed to determine the methylation patterns in genes involved in the development of COPD resulting from exposure to biomass-burning smoke (COPD-BBS). EWAS was conducted on induced sputum samples from 45 women with stable COPD (COPD-BBS) exposure and 45 women exposed to BBS but without the disease (BBES). Proteins whose genes showed significant differences in methylation and were soluble in the induced sputum supernatant were quantified. 205 CpG sites were found differentially hypomethylated, and 420 were hypermethylated. The top 50 show genes associated with lung remodeling (FOXP1 p = 0.002, FMOD p = 0.012, EDN1 p = 0.044), the immune system (ALOX5 p = 0.005, IL19 p = 0.047), mucus production (MUC19 p = 0.04), and xenobiotic metabolism (GSTO2 p = 0.02). Of the proteins evaluated, endothelin-1 was decreased in the reference group compared to patients (p = 0.00054). Gene methylation changes are linked to lung remodeling, immune response, mucus production, and xenobiotic metabolism. Hypermethylation of the cg08450425 site (EDN1) is significant in women with COPD and associated with low endothelin-1 levels.

30 October 2026 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
IFIngrid Fricke-Galindo
Ingrid Fricke-Galindo
FOFrancisco M. Ortega‐Villafuerte
Francisco M. Ortega‐Villafuerte
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
Julian Ramírez-BelloJulian Ramírez-Bello
Julian Ramírez-Bello
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
We aimed to evaluate the association between IL10 variants and plasma IL‐10 levels and clinical outcomes in patients with severe COVID‐19 treated with corticosteroids. We studied 944 patients with severe COVID‐19 who were treated with corticosteroids. The clinical outcomes evaluated were in‐hospital mortality and the requirement of invasive mechanical ventilation (IMV). The variants IL10 rs1800872, rs1554286, rs3024505, and rs3122605 were determined using TaqMan SNP assays, and IL‐10 levels were measured by ELISA at the start of corticosteroid treatment (T1) and after 8 days (T2). The rs1800872‐TT ( p = 0.035, OR = 1.55, 95% CI = 1.03–2.33) and the rs1554286‐AA genotypes were associated with IMV ( p adj = 0.036, OR = 2.42, 95% CI = 1.12–5.95). IL‐10 levels were higher at T1 than at T2. At T2, IL‐10 levels were higher in non‐survivors (15.9 vs. 7.0 pg/mL, p < 0.001) and in patients requiring IMV (9.9 vs. 5.5 pg/mL, p < 0.001). Among non‐survivors, IL‐10 plasma levels did not decrease at T2. The alluvial plot revealed that 51.9% of patients in the highest IL‐10 tertile at T1 remained in the highest tertile at T2, with a mortality rate of 50%. IL10 rs1800872 and rs1554286 contribute to the risk of requiring IMV. Elevated IL‐10 levels after corticosteroid treatment were linked to in‐hospital mortality and IMV.